Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma

The addition of anti-disialoganglioside-2 (GD2) monoclonal antibodies (mAbs) such as dinutuximab and naxitamab to standard therapies for high-risk (HR) neuroblastoma has significantly improved outcomes for children with this devastating disease. The care for these young patients receiving treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabral, Jennifer, Fernandez, Erica I., Toy, Bonnie, Secola, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Therapy in Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017787/
https://www.ncbi.nlm.nih.gov/pubmed/36434427
http://dx.doi.org/10.1007/s40272-022-00544-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017787/
https://www.ncbi.nlm.nih.gov/pubmed/36434427
http://dx.doi.org/10.1007/s40272-022-00544-9

Ejemplares similares